News | Enterprise Imaging | April 07, 2021

Survey Shows Widespread Lack of Awareness and Readiness to Comply with Federal Mandate by April 5, 2021 Enforcement Date

As ONC starts enforcement, organizations must prioritize deepening their knowledge of these mandates and implementing changes to adapt to the evolving landscape, or run the risk of incurring significant penalties

As ONC starts enforcement, organizations must prioritize deepening their knowledge of these mandates and implementing changes to adapt to the evolving landscape, or run the risk of incurring significant penalties

April 7, 2021 — Life Image, a medical evidence network for clinical and imaging data, released findings of its survey investigating the healthcare industry’s preparedness to comply with the Information Blocking and Improving Interoperability provisions of the Office of the National Coordinator for Health IT (ONC) Final Rule of the 2016 Cures Act, which will be enforced starting April 5, 2021. Findings from the survey, sent in March 2021 to nearly 4,000 clinical, technology and administrative leaders from provider, payer, IT, and other organizations, demonstrate a broad lack of awareness and readiness to comply with the federal information blocking rules, meaning many organizations do not meet basic interoperability standards. The survey also indicates general confusion around the rule requirements and the specific steps organizations must take to prepare.

The final ONC rules aim to improve electronic access, exchange, and use of health information, granting patients ownership of their health data without special effort or additional cost. While 70% of participants in the Life Image survey stated they were aware of the rules going into effect, up to half of the same individuals also reported using practices that are defined by ONC as information blocking and will be noncompliant under the new rules – such as sharing records via paper or CDs, or charging patients fees to obtain records.

Additional notable findings from the Life Image survey include:

  • Nearly half of the respondents had either not made any changes or did not know how to ensure their facility meets all of the rule requirements
  • A majority of healthcare organizations reported not using digital solutions to share healthcare data with patients, with 66% still using paper and 32% using CDs
  • 47% were not familiar with the term “information blocking”
    • 48% were not aware of practices or policies that would be considered “information blocking”
  • 39% did not know they could incur civil monetary penalties for information blocking practices
  • 15% currently charge $25 or more for patients to obtain records

“Our recent survey validates what Life Image has been witnessing across the healthcare ecosystem in terms of interoperability readiness. While the COVID-19 pandemic created massive challenges and delayed many interoperability initiatives, it also underscored the paramount importance of the final ONC rules for advancing patient care and driving innovation,” said Matthew A. Michela, President and CEO, Life Image. “As many organizations are facing a long, complicated journey to ONC compliance, we’re dedicated to helping the industry navigate this new data revolution.”

Under HIPAA 45 CFR § 164.524, providers must give patients, upon request, access to their protected health information in the form and format of the individual’s choosing, including electronic format and via third-party application. In order to address ongoing industry resistance and barriers to interoperability, in March 2020 the ONC released the Final Cures Act Rule, which is grounded in the 21st Century Cures Act and mandates that patients be allowed greater control and access to their health data, targeting vendors and technologies that block information access.

David Schoolcraft, Partner and Chair of the Digital Health Group at Ogden Murphy Wallace, sees this as a pivotal moment for healthcare’s digital transformation. “This landmark regulation is also a massive undertaking as many stakeholders are currently non-compliant and are struggling to navigate the regulatory complexities,” he said. “As ONC starts enforcement, organizations must prioritize deepening their knowledge of these mandates and implementing changes to adapt to the evolving landscape, or run the risk of incurring significant penalties.”

Life Image began working to solve healthcare’s interoperability challenges nearly 15 years ago, developing a digital platform with applications using common standards to streamline the rapid exchange of medical images and related data. The company is now the largest global medical evidence network specializing in the sharing of imaging data and related clinical information. It offers a mature technical solution used by 90% of the top hospitals in the United States.

For more information: www.lifeimage.com

Related Content

The U.S. Food and Drug Administration (#FDA) authorized marketing of #Medtronic's #GIGenius, the first device that uses #artificialintelligence (#AI) based on #machinelearning to assist #clinicians in detecting #lesions (such as #polyps or suspected tumors) in the #colon in real time during a c#olonoscopy.

The GI Genius intelligent endoscopy module works in real-time, automatically identifying and marking (with a green box) abnormalities consistent with colorectal polyps, including small flat polyps.

News | Artificial Intelligence | April 12, 2021
Varian announced it is collaborating with Google Cloud to build an advanced artificial intelligence (AI) based diagnostic platform to aid in the fight against cancer. Varian and Google Cloud AI embarked on a deployment journey, using Neural Architecture Search (NAS) technology via Google Cloud AI Platform, to create AI models for organ segmentation — a crucial and labor-intensive step in radiation oncology that can be a bottleneck in the cancer treatment clinical workflow.
News | Artificial Intelligence | April 08, 2021
April 8, 2021 — Varian announced it is collaborating with Google...
Ultrasound is an invaluable diagnostic tool for the early detection of breast cancer, but the classification of lesions is sometimes challenging and time consuming. Could artificial intelligence hold the answer to solving these problems? Graphic courtesy of Chinese Medical Journal

Ultrasound is an invaluable diagnostic tool for the early detection of breast cancer, but the classification of lesions is sometimes challenging and time consuming. Could artificial intelligence hold the answer to solving these problems? Graphic courtesy of Chinese Medical Journal

News | Artificial Intelligence | April 06, 2021
April 6, 2021 — In 2020, the International Agency for Research on...
Nano-X Imaging Ltd (Nanox), an innovative medical imaging technology company, announced that its single-source Nanox.ARC digital x-ray technology has received 510(k) clearance from the US Food and Drug Administration.
News | X-Ray | April 02, 2021
April 2, 2021 — Nano-X Imaging Ltd.
Elsevier’s STATdx, a leading radiology diagnostic decision support solution, now includes select Merit-Based Incentive Payment System (MIPS) Measures validated by MDinteractive
News | Clinical Decision Support | April 02, 2021
April 2, 2021 — Elsevier, a global leader in research publishing and information analytics, announced a partnership w
ScImage, Inc. celebrates its cloud partnership with Digirad Health (“Digirad”), a division of Star Equity Holdings, after a year of successful deployment of PICOM365 for mobile imaging. Digirad’s fleet of mobile SPECT, echocardiology, vascular and general ultrasound units combined with PICOM365’s cloud image management workflow leverage each company’s strengths to create an exemplary reading and reporting environment.
News | Archive Cloud Storage | March 30, 2021
March 30, 2021 — ScImage, Inc.
Nines announced the 510(k) FDA clearance for NinesMeasure, an innovative lung nodule measurement tool built with artificial intelligence (AI) that can accelerate diagnoses of certain respiratory diseases. 
News | Artificial Intelligence | March 30, 2021
March 30, 2021 — Nines announced the 510(k) FDA clearance for NinesMeasure, an innovative...